accountInc., a biopharmaceutical company with 3 clinical stage candidates, has announced today that the draft Clinical Study Report (CSR) from CG400549's Phase I Multiple Ascending Dose (MAD) Study has just been received. CG400549 is a potential first-in-class...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to CrystalGenomics Completes Phase I MAD Study Of Its Novel Antibiotic Candidate CG400549, And Prepares For Phase II Clinical Study
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account